It was noteworthy that there was a certain proportion of FCGR3A copy number deletion in stomach adenocarcinoma, prostate adenocarcinoma, and kidney renal papillary cell carcinoma. This evidence concerns the gene FCGR3A and gastric adenocarcinoma.